Phase II study of gefitinib treatment in advanced thymic malignancies

作者: A. Kurup , M. Burns , S. Dropcho , W. Pao , P. J. Loehrer

DOI: 10.1200/JCO.2005.23.16_SUPPL.7068

关键词: Epidermal growth factor receptorThymic carcinomaToxicityPrior Radiation TherapyThymomaPhases of clinical researchMedicineECOG Performance StatusOncologyInternal medicineGefitinib

摘要: 7068 Background: Thymomas and thymic carcinomas are rare epithelial tumors arising from the thymus gland. Malignant have shown to express epidermal growth factor receptor (EGFR). This study evaluates activity of gefitinib, an EGFR tyrosine kinase inhibitor, in patients (pts) with advanced thymoma/thymic carcinoma. Objectives: Primary objective was determine response rate gefitinib previously treated pts, thymoma or Secondary objectives were duration remission toxicity. Methods: Twenty-six (female = 15, male 11) pts metastatic (n 19) carcinoma 7), ECOG performance status 0 1, enrolled January 21, 2003 June 14, 2004. Nineteen had prior radiation therapy. Median number systemic therapies 2.5 (range, - 6). Pts received orally at 250 mg daily. Each treatment cycle 28 days. obtaining a complete (...

参考文章(0)